

2019 State Profile — Oregon

National Survey of Substance Abuse Treatment Services (N-SSATS)

The National Survey of Substance Abuse Treatment Services (N-SSATS) is an annual survey of facilities providing substance abuse treatment. It is conducted by the Substance Abuse and Mental Health Services Administration (SAMHSA). The N-SSATS collects data on the location, characteristics, services offered, and number of clients (collected every other year) in treatment at alcohol and drug abuse treatment facilities (public and private) throughout the 50 states, the District of Columbia, U.S. territories, and other jurisdictions.

More information on the methodology used is available in the 2019 N-SSATS report:

<https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

In Oregon, 234 substance abuse treatment facilities were included in the 2019 N-SSATS report, which reported a total of 20,268 clients in substance abuse treatment on March 29, 2019. The survey response rate in Oregon was 89.1 percent.

Facility operation, by number and percent

	Facilities		Clients in treatment on March 29, 2019			
			All clients		Clients under the age of 18 years	
	No.	%	No.	%	No.	%
Private non-profit	125	53.4	10,807	53.3	493	46.5
Private for-profit	74	31.6	6,136	30.3	140	13.2
Local, county, or community government	22	9.4	2,210	10.9	198	18.7
State government	1	0.4	14	0.1	—	—
Federal government	4	1.7	579	2.9	215	20.3
Tribal government	8	3.4	522	2.6	14	1.3
Total	234	100.0	20,268	100.0	1,060	100.0

Note: Percentages may not sum to 100 percent due to rounding.

Substance abuse problem treated, by number and percent

	Facilities ¹		Clients in treatment on March 29, 2019		
			Clients ²		Clients ² per 100,000 pop. aged 18 years or older
	No.	%	No.	%	
Clients with both alcohol and drug abuse	165	90.7	6,812	34.0	190
Clients with drug abuse only	162	89.0	9,698	48.5	277
Clients with alcohol abuse only	144	79.1	3,502	17.5	101
Total			20,011	100.0	568

¹ Numbers of facilities may sum to more than the total, and percentages may sum to more than 100 percent, because facilities may be included in more than one category.

² States report *substance abuse problem treated* in terms of percentages of clients, from which the numbers of clients in this table are derived; their sum may not agree with the total due to rounding.

Facility capacity and utilization rate¹

	Residential	Hospital inpatient
Number of facilities	29	4
Number of clients ²	629	36
Number of designated beds	726	58
Utilization rate ³	86.6	62.1
Average number of designated beds per facility	25	15

¹ Excludes facilities not reporting both client counts and number of beds, facilities whose client counts were reported by another facility, facilities that included client counts from other facilities, and facilities that did not respond to this question.

² Number of clients on March 29, 2019.

³ Because substance abuse treatment clients may also occupy non-designated beds, utilization rates may be more than 100 percent.

For a symbol key, see the last page of this profile.

Type of care, by number and percent

	Clients in treatment on March 29, 2019							
	Facilities		All clients				Clients under the age of 18 years	
	No.	%	No.	%	Median no. of clients per OTP facility	Median no. of clients per non-OTP facility	No.	%
Outpatient	208	88.9	19,520	96.3	232	57	930	87.7
Regular	198	84.6	10,782	53.2	193	40		
Intensive	135	57.7	2,610	12.9	15	15		
Day treatment or partial hospitalization	33	14.1	377	1.9	16	8		
Detoxification	22	9.4	9	*	—	2		
Methadone/buprenorphine maintenance or naltrexone treatment	74	31.6	5,742	28.3	232	26		
Residential (non-hospital)	34	14.5	705	3.5	—	20	130	12.3
Short term (≤ 30 days)	24	10.3	251	1.2	—	11		
Long term (> 30 days)	25	10.7	397	2.0	—	15		
Detoxification	19	8.1	57	0.3	—	5		
Hospital inpatient	6	2.6	43	0.2	—	7	—	—
Treatment	3	1.3	6	*	—	—		
Detoxification	6	2.6	37	0.2	—	7		
Total	234		20,268	100.0	232	46	1,060	100.0

Note: Facilities may provide more than one type of care.

Facility licensing, certification, or accreditation, by number and percent

	No.	%
Any listed agency/organization	225	96.2
State substance abuse agency	215	91.9
State mental health department	121	51.7
State department of health	75	32.1
Hospital licensing authority	6	2.6
The Joint Commission	16	6.8
Commission on Accreditation of Rehabilitation Facilities (CARF)	31	13.2
National Committee for Quality Assurance (NCQA)	1	0.4
Council on Accreditation (COA)	8	3.4
Healthcare Facilities Accreditation Program (HFAP)	—	—
Other national organization or federal, state, or local agency	9	3.8

Note: Facilities may be licensed, certified, or accredited by more than one agency/organization.

Facility payment options, by number and percent

	No.	%
Cash or self-payment	220	94.0
Private health insurance	205	87.6
Medicare	74	31.6
Medicaid	210	89.7
State-financed health insurance plan other than Medicaid	153	65.4
Federal military insurance	96	41.0
No payment accepted (free treatment for all clients)	—	—
IHS/Tribal/Urban (ITU) funds	76	32.5
Other	—	—
Sliding fee scale	172	73.5
Treatment at no charge or minimal payment for clients who can't pay	129	55.1

Note: Facilities may accept more than one type of payment.

Types of services offered, by number and percent

	Facilities	
	No.	%
Assessment and pre-treatment services		
Screening for substance abuse	220	94.0
Screening for mental health disorders	178	76.1
Comprehensive substance abuse assessment or diagnosis	225	96.2
Comprehensive mental health assessment or diagnosis	113	48.3
Screening for tobacco use	214	91.5
Outreach to persons in the community who may need treatment	168	71.8
Interim services for clients when immediate admission is not possible	137	58.5
Professional interventionist/educational consultant	34	14.5
None of these assessment and pre-treatment services offered	—	—
Testing		
Drug and alcohol oral fluid testing	73	31.2
Breathalyzer or other blood alcohol testing	114	48.7
Drug or alcohol urine screening	232	99.1
Testing for hepatitis B	59	25.2
Testing for hepatitis C	65	27.8
HIV testing	66	28.2
STD testing	57	24.4
TB screening	74	31.6
Testing for metabolic syndrome	19	8.1
None of these testing services offered	2	0.9
Medical services		
Hepatitis A (HAV) vaccination	25	10.7
Hepatitis B (HBV) vaccination	23	9.8
None of these medical services offered	208	88.9
Transitional services		
Discharge planning	229	97.9
Aftercare/continuing care	209	89.3
Naloxone and overdose education	103	44.0
Outcome follow-up after discharge	138	59.0
None of these transitional services offered	1	0.4
Recovery support services		
Mentoring/peer support	167	71.4
Self-help groups (for example, AA, NA, SMART Recovery)	127	54.3
Assistance in locating housing for clients	184	78.6
Employment counseling or training for clients	105	44.9
Assistance with obtaining social services (for example, Medicaid, WIC, SSI, SSDI)	177	75.6
Recovery coach	55	23.5
None of these recovery support services offered	13	5.6
Education and counseling services		
HIV or AIDS education, counseling, or support	148	63.2
Hepatitis education, counseling, or support	139	59.4
Health education other than HIV/AIDS or hepatitis	146	62.4
Substance abuse education	228	97.4
Smoking/ tobacco cessation counseling	174	74.4
Individual counseling	227	97.0

Continued

For a symbol key, see the last page of this profile.

Types of services offered, by number and percent (continued)

	Facilities	
	No.	%
Group counseling	221	94.4
Family counseling	197	84.2
Marital/couples counseling	138	59.0
Vocational training or educational support	36	15.4
None of these education and counseling services offered	4	1.7
Pharmacotherapies		
Disulfiram (Antabuse®)	35	15.0
Naltrexone (oral)	63	26.9
Naltrexone (extended-release, injectable, for example, Vivitrol®)	57	24.4
Acamprosate (Campral®)	32	13.7
Nicotine replacement	76	32.5
Non-nicotine smoking/tobacco cessation medications (for example, bupropion, varenicline)	63	26.9
Medications for psychiatric disorders	94	40.2
Methadone ¹	19	8.1
Buprenorphine with naloxone (for example, Suboxone®, Bunavail®, Zubsolv®, Cassipa®)	77	32.9
Buprenorphine without naloxone	55	23.5
Buprenorphine sub-dermal implant (Probuphine®)	9	3.8
Buprenorphine (extended-release, injectable, for example, Sublocade®)	19	8.1
Medications for HIV treatment (for example, antiretroviral medications such as tenofovir, efavirenz, emtricitabine, atazanavir, and lamivudine)	15	6.4
Medications for hepatitis C (HCV) treatment (for example, sofosbuvir, ledipasvir, interferon, peginterferon, ribavirin)	16	6.8
Lofexidine	13	5.6
Clonidine	49	20.9
None of these pharmacotherapy services offered	92	39.3
Ancillary services		
Case management services	206	88.0
Social skills development	190	81.2
Child care for clients' children	25	10.7
Domestic violence—family or partner violence services (physical, sexual, and emotional abuse)	103	44.0
Early intervention for HIV	52	22.2
Transportation assistance to treatment	135	57.7
Mental health services	153	65.4
Acupuncture	17	7.3
Residential beds for clients' children	7	3.0
None of these ancillary services offered	14	6.0
Other services		
Treatment for gambling disorder	81	34.6
Treatment for Internet use disorder	24	10.3
Treatment for other addiction disorder (non-substance abuse)	74	31.6
None of these 'other' services offered	120	51.3

¹ Methadone is available only at OTP facilities that are certified by SAMHSA's Center for Substance Abuse Treatment.

Clinical/therapeutic approaches used frequently, by number and percent

	Facilities	
	No.	%
Substance abuse counseling	229	97.9
12-step facilitation	159	67.9
Brief intervention	188	80.3
Cognitive behavioral therapy	219	93.6
Dialectical behavior therapy	181	77.4
Contingency management/motivational incentives	138	59.0
Motivational interviewing	225	96.2
Trauma-related counseling	207	88.5
Anger management	180	76.9
Matrix model	126	53.8
Community reinforcement plus vouchers	29	12.4
Rational emotive behavioral therapy (REBT)	101	43.2
Relapse prevention	226	96.6
Telemedicine/telehealth	62	26.5
Other treatment approaches	33	14.1
We do not use any of these clinical/therapeutic approaches	—	—

Specifically tailored programs or groups, by number and percent

	Facilities	
	No.	%
Any program or group	217	92.7
Adolescents	68	29.1
Young adults	84	35.9
Adult women	144	61.5
Pregnant or postpartum women	61	26.1
Adult men	133	56.8
Seniors or older adults	52	22.2
LGBT clients	57	24.4
Veterans	52	22.2
Active duty military	26	11.1
Members of military families	24	10.3
Criminal justice clients (other than DUI/DWI)	112	47.9
Clients with co-occurring mental and substance use disorders	138	59.0
Clients with co-occurring pain and substance use	61	26.1
Clients with HIV or AIDS	37	15.8
Clients who have experienced sexual abuse	72	30.8
Clients who have experienced intimate partner violence, domestic violence	78	33.3
Clients who have experienced trauma	131	56.0
DUI/DWI clients	127	54.3
Other	24	10.3
No specifically tailored programs or groups are offered	17	7.3

DUI/DWI = driving under the influence/driving while intoxicated or impaired; LGBT = lesbian, gay, bisexual, or transgender.

Facility funding, by number and percent

	Facilities	
	No.	%
Receives federal, state, county, or local government funds or grants for substance use treatment programs	136	58.1

Services in sign language for the deaf and hard-of-hearing and in languages other than English, by number and percent

	Facilities	
	No.	%
Sign language	106	45.3
Any language other than English	151	64.5

Non-English language provided by

Staff counselor only	35	23.2
On-call interpreter only	85	56.3
Both staff counselor and on-call interpreter	31	20.5

Languages provided by staff counselor¹

Spanish	59	89.4
American Indian/Alaska Native languages	—	—
Other	10	15.2

¹ Numbers and percentages are based on facilities that provide language services through a staff counselor, either exclusively or in conjunction with on-call interpreters.

Symbol key (where applicable)

— Quantity is zero; * Less than 0.05 percent;
† Less than 1 per 100,000; ‡ No facilities in this category.

Data in this profile are from facilities that reported to the N-SSATS and are based on the survey's reference date, March 29, 2019. All material in this profile is in the public domain and may be reproduced without permission from SAMHSA. Citation of the source is appreciated.

The latest N-SSATS report, and other substance abuse reports, are available at: <https://www.samhsa.gov/data/data-we-collect/n-ssats-national-survey-substance-abuse-treatment-services>

Access the latest N-SSATS public use files at:
<https://datafiles.samhsa.gov>

For information on individual facilities, access SAMHSA's Behavioral Health Treatment Services Locator at:
<https://findtreatment.samhsa.gov/>



U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
Substance Abuse and Mental Health Services Administration
Center for Behavioral Health Statistics and Quality
www.samhsa.gov/data

Clients receiving medication-assisted opioid therapy (MAOT) at facilities with opioid treatment programs (OTPs) and non-OTP facilities, by number and percent

	No.	%
Facilities with OTPs¹	19	1.1
Clients in facilities with OTPs²		
Any MAT ³	5,816	1.3
Methadone	5,146	1.3
Buprenorphine	665	1.9
Naltrexone	5	0.2
Clients in facilities without OTPs⁴		
Any MAT ⁵	1,514	0.9
Buprenorphine	1,311	1.0
Naltrexone	203	0.7


¹ Percentage of all facilities with OTPs in the U.S. ² Percentage of all clients receiving methadone, buprenorphine, or naltrexone at facilities with OTPs in the U.S.; see 2019 N-SSATS report for details. ³ Consists of clients receiving methadone, buprenorphine, or naltrexone. ⁴ Percentage of all clients receiving buprenorphine or naltrexone at non-OTP facilities in the U.S.; see 2019 N-SSATS report for details. ⁵ Consists of clients receiving buprenorphine or naltrexone.

Clients per 100,000 population receiving MAOT in OTP facilities on March 29, 2019

	No.
Any type of medication-assisted therapy ¹	138
Methadone	122
Buprenorphine	16
Naltrexone	†

¹ Includes clients receiving methadone, buprenorphine, or naltrexone.

Location of treatment facilities



<https://www.samhsa.gov/data/quick-statistics>